Repligen (NASDAQ:RGEN) Upgraded to “Moderate Buy” at Royal Bank Of Canada

Repligen (NASDAQ:RGEN) was upgraded by equities research analysts at Royal Bank Of Canada to a “moderate buy” rating in a report released on Thursday,Zacks.com reports.

A number of other analysts also recently weighed in on RGEN. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. UBS Group reduced their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. HC Wainwright raised their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Finally, Canaccord Genuity Group reduced their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.15.

Repligen Stock Performance

Shares of Repligen stock opened at $102.87 on Thursday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The business has a 50-day moving average price of $118.96 and a two-hundred day moving average price of $142.18. Repligen has a 1-year low of $100.99 and a 1-year high of $175.77. The company has a market cap of $5.80 billion, a P/E ratio of 114.30, a PEG ratio of 1.99 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period last year, the business posted $0.39 EPS. The business’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts anticipate that Repligen will post 1.99 EPS for the current year.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Granahan Investment Management LLC increased its position in Repligen by 20.8% in the 1st quarter. Granahan Investment Management LLC now owns 86,953 shares of the biotechnology company’s stock valued at $10,245,000 after buying an additional 14,951 shares in the last quarter. Wealth Alliance LLC increased its position in Repligen by 18.1% in the 1st quarter. Wealth Alliance LLC now owns 2,529 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 387 shares in the last quarter. Public Employees Retirement System of Ohio increased its position in Repligen by 16.9% in the 1st quarter. Public Employees Retirement System of Ohio now owns 52,811 shares of the biotechnology company’s stock valued at $6,222,000 after buying an additional 7,649 shares in the last quarter. Gibbs Wealth Management increased its position in Repligen by 99.9% in the 1st quarter. Gibbs Wealth Management now owns 10,713 shares of the biotechnology company’s stock valued at $1,262,000 after buying an additional 5,353 shares in the last quarter. Finally, Sei Investments Co. increased its position in Repligen by 49.5% in the 1st quarter. Sei Investments Co. now owns 272,103 shares of the biotechnology company’s stock valued at $32,061,000 after buying an additional 90,115 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.